KYMR - Dividend announcements

Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines and favorable safety profile. HS and AD patient cohort data expected in 2H22 INDs cleared and Phase 1 clinical studies initiated for STAT3 (KT-333) and IRAKIMiD (KT-413), with proof of mechanism data expected in 2022 First disclosure of KT-253, a first-in-class potent and selective MDM2 degrader targeting the p53 pathway for the treatment of liquid and solid tumors, with IND filing expected in 2H22 First disclosure of tissue sparing degradation, with program

Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 initiated in February; on track to present human proof-of-biology data in 4Q 2021 Oncology degrader programs KT-413 and KT-333 expected to enter clinical development in 2H 2021 WATERTOWN, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the first quarter ended March 31, 2021. "This month marks Kymera's five-year anniversary, going from idea generation to clinical entry, and now towards becoming a

Initiated Phase 1 first-in-human dosing of KT-474, a first-in-class oral IRAK4 degrader to treat immune-inflammatory diseases Declared KT-333 as STAT3 development candidate for liquid and solid tumor indications and commenced IND-enabling activities Strong financial position to support continued execution and pipeline growth; inaugural R&D Day to highlight five-year company vision WATERTOWN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the fourth qu